Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs PT Telekomunikasi Indonesia Tbk (TLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs PT Telekomunikasi Indonesia Tbk — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while PT Telekomunikasi Indonesia Tbk trades at $12.71 (market cap $12.31B). The key difference: PT Telekomunikasi Indonesia Tbk is far larger — about 12.7× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and PT Telekomunikasi Indonesia Tbk pays a 9.66% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and PT Telekomunikasi Indonesia Tbk for 1 Days on average.
| MRVI | TLK | |
|---|---|---|
Market Cap | $972.90M | $12.31B |
Volume | 4,325,710 | 964,895 |
Sector | Health | Media |
52-Week High | $9.00 | $23.43 |
52-Week Low | $2.83 | $12.42 |
Typical Hold Time | 0 Days | 1 Days |
Enterprise Value | $1.08B | $13.67B |
Dividend Yield | — | 9.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
TLK trades at $12.65, down 1.02% on the day, with a bearish technical signal driven by moving averages. The stock shows mixed earnings performance with two recent misses but a Q2 2026 beat. Fundamentals remain solid with a 66.88% gross margin and attractive valuation at P/E of 12.72 and EV/EBITDA of 3.27. Recent news includes a 52-week low hit in September 2026 and institutional buying activity.
The outlook is cautious with 100% hold ratings from analysts and bearish technical indicators. Investment opportunity lies in deep value metrics and positive 5G developments, but risks include earnings volatility and competitive pressures in the telecommunications sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About PT Telekomunikasi Indonesia Tbk
Telkom Indonesia provides mobile, fixed-line, broadband, and digital services in Indonesia. Its businesses include Telkomsel, which serves the country’s mobile market.
Read more on TLK →
